CoChat
Sign Up
Cited by 5Schizophrenia research and treatmentGenetic Associations and EpidemiologyLipoproteins and Cardiovascular Health

Homozygosity in the APOE 3 Polymorphism Is Associated With Less Depression and Higher Serum Low-Density Lipoprotein in Chinese Elderly Schizophrenics

Open access
Li, Wei, Ban, Chunxia, Yue, Ling, Sun, Lin, Li, Xia, Xiao, Shifu·2020·Frontiers in Endocrinology
DOI 10.3389/fendo.2020.00642PMC PMC7593819
Open this paper in CoChat — free accountOpen PDF

Abstract

Background Depressive symptoms are common comorbidities in schizophrenia. However, the effect of APOE E3 on depressive symptoms has never been investigated in Chinese aging with schizophrenia. Objective This cross-sectional study was to investigate the effect of APOE E3 on blood lipid metabolism and depressive symptoms in Chinese elderly schizophrenics. Method: 301 elderly schizophrenics (161 males, age ranges from 60 to 92 years, with an average age of 67.31±6.667) were included in the study. Depressive symptoms were assessed using the Geriatric Depression Scale (GDS). And APOE gene polymorphism was determined by polymerase chain reaction (PCR). Correlations of GDS and serum low density lipoprotein (LDL) with APOE genotypes were assessed. Results The concentration of LDL in APOE E3 group was significantly higher than that in without APOE group, while the scores of GDS of APOE E3 group were lower than that in without APOE E3 group. By using partial correlation analysis and controlling age, gender, duration of disease and hyperlipidemia, we found that the scores of GDS were significantly correlated with LDL (r=-0.194, p= 0.016). Conclusions APOE E3 is associated with less depressive symptoms and higher serum LDL in Chinese elderly patients with schizophrenia, and there is a negative correlation between depressive symptoms and LDL.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2020.00642

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 30

  1. [1]Felmet K Zisook S Kasckow JW. Elderly patients with schizophrenia and depression: diagnosis and treatment. Clin. Schizophr. Relat. Psychoses. (2011) 4: 239– 50. 10.3371/CSRP.4.4.4 21177241 PMC3062362 · DOI
  2. [2]Xu YM Li F Liu XB Zhong BL. Depressive symptoms in Chinese male inpatients with schizophrenia: prevalence and clinical correlates. Psychiatry Res. (2018) 264: 380– 84. 10.1016/j.psychres.2018.04.016 29677621 · DOI
  3. [4]Peitl V Vidrih B Karlovic Z Getaldic B Peitl M Karlovic D. Platelet serotonin concentration and depressive symptoms in patients with schizophrenia. Psychiatry Res. (2016) 239: 105– 10. 10.1016/j.psychres.2016.03.006 27137969 · DOI
  4. [5]Majadas S Olivares J Galan J Diez T. Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. Compr. Psychiatry. (2012) 53: 145– 51. 10.1016/j.comppsych.2011.03.009 21621754 · DOI
  5. [6]Cotton SM Lambert M Schimmelmann BG Mackinnon A Gleeson JF Berk M. Depressive symptoms in first episode schizophrenia spectrum disorder. Schizophr. Res. (2012) 134: 20– 6. 10.1016/j.schres.2011.08.018 21937197 · DOI
  6. [7]Zhou X Wang J Lu Y Chen C Hu Y Liu P. Anti-depressive effects of Kai-Xin-San on lipid metabolism in depressed patients and CUMS rats using metabolomic analysis. J Ethnopharmacol. (2020) 252: 112615. 10.1016/j.jep.2020.112615 31991203 · DOI
  7. [9]Poirier J Davignon J Bouthillier D Kogan S Bertrand P Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. (1993) 342: 697– 99. 10.1016/0140-6736(93)91705-Q 8103819 · DOI · Paper page
  8. [10]Lopez-Leon S Janssens AC Gonzalez-Zuloeta Ladd AM Del-Favero J Claes SJ Oostra BA. Meta-analyses of genetic studies on major depressive disorder. Mol. Psychiatry. (2008) 13: 772– 85. 10.1038/sj.mp.4002088 17938638 · DOI
  9. [11]Skoog I Waern M Duberstein P Blennow K Zetterberg H Börjesson-Hanson A. A 9-year prospective population-based study on the association between the APOE*E4 allele and late-life depression in Sweden. Biol. Psychiatry. (2015) 78: 730– 36. 10.1016/j.biopsych.2015.01.006 25708227 · DOI · Paper page
  10. [12]Corbo RM Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty' allele? Ann. Hum. Genet. (1999) 63(Pt 4): 301– 10. 10.1046/j.1469-1809.1999.6340301.x 10738542 · DOI
  11. [13]Leduc V Domenger D De Beaumont L Lalonde D Belanger-Jasmin S Poirier J. Function and comorbidities of apolipoprotein e in Alzheimer's disease. Int. J. Alzheimers Dis. (2011) 2011: 974361. 10.4061/2011/974361 21559182 PMC3089878 · DOI
  12. [14]Ban C Zhang Q Feng J Li H Qiu Q Tian Y Low prevalence of lipid metabolism abnormalities in APOE epsilon2-genotype and male patients 60 years or older with schizophrenia. BMC Psychiatry. (2017) 17: 399 10.1186/s12888-017-1530-9 29233125 PMC5727937 · DOI
  13. [15]Smith K. Mental health: a world of depression. Nature. (2014) 515: 181. 10.1038/515180a 25391942 · DOI · Paper page
  14. [16]Lin X Haralambous B Pachana NA Bryant C LoGiudice D Goh A. Screening for depression and anxiety among older Chinese immigrants living in Western countries: the use of the Geriatric Depression Scale (GDS) and the Geriatric Anxiety Inventory (GAI). Asia Pac. Psychiatry. (2016) 8: 32– 43. 10.1111/appy.12191 26010903 · DOI
  15. [17]Albinski R Kleszczewska-Albinska A Bedynska S. Geriatric depression scale (GDS). validity and reliability of different versions of the scale—review. Psychiatr. Pol. (2011) 45: 555– 62. 22232981
  16. [18]Nasreddine ZS Phillips NA Bedirian V Charbonneau S Whitehead V Collin I The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. (2005) 53: 695– 99. 10.1111/j.1532-5415.2005.53221.x 15817019 · DOI · Paper page
  17. [19]Fisekovic S Memic A Pasalic A. Correlation between moca and mmse for the assessment of cognition in schizophrenia. Acta Inform. Med. (2012) 20: 186– 89. 10.5455/aim.2012.20.186-189 23322976 PMC3508854 · DOI
  18. [20]Aboraya A Nasrallah HA. Perspectives on the positive and negative syndrome scale (PANSS): use, misuse, drawbacks, and a new alternative for schizophrenia research. Ann. Clin. Psychiatry. (2016) 28: 125– 31. 26855990
  19. [21]Kay SR Fiszbein A Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. (1987) 13: 261– 76. 10.1093/schbul/13.2.261 3616518 · DOI · Paper page
  20. [22]Rabinowitz J Schooler NR Anderson A Ayearst L Daniel D Davidson M. Consistency checks to improve measurement with the positive and negative syndrome scale (PANSS). Schizophr Res. (2017) 190: 74– 6. 10.1016/j.schres.2017.03.017 28285023 PMC5662474 · DOI
  21. [23]Donohoe GG Salomaki A Lehtimaki T Pulkki K Kairisto V. Rapid identification of apolipoprotein E genotypes by multiplex amplification refractory mutation system PCR and capillary gel electrophoresis. Clin Chem. (1999) 45: 143– 46. 10.1093/clinchem/45.1.143 9895356 · DOI
  22. [24]Gibbons AS Udawela M Jeon WJ Seo MS Brooks L Dean B The neurobiology of APOE in schizophrenia and mood disorders. Front. Biosci. (2011) 16: 962– 79. 10.2741/3729 21196212 · DOI
  23. [25]Schurhoff F Krebs MO Szoke A Loze JY Goldberger C Quignon V Apolipoprotein E in schizophrenia: a French association study and meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2003) 119b: 18– 23. 10.1002/ajmg.b.20007 12707932 · DOI
  24. [26]Kampman O Anttila S Illi A Mattila KM Rontu R Leinonen E Apolipoprotein E polymorphism is associated with age of onset in schizophrenia. J. Hum. Genet. (2004) 49: 355– 59. 10.1007/s10038-004-0157-0 15221639 · DOI
  25. [27]Guan S Yang J Tang Z Fang X Wu X Sun F. The relationship between apolipoprotein (apo) E polymorphism and lipid changes: an 8-year cohort study in Beijing elderly persons. Arch. Gerontol. Geriatr. (2012) 55: 713– 17. 10.1016/j.archger.2011.12.001 22206590 · DOI
  26. [28]Persons JE Fiedorowicz JG Depression and serum low-density lipoprotein: a systematic review and meta-analysis. J. Affect. Disord. (2016) 206: 55– 67. 10.1016/j.jad.2016.07.033 27466743 PMC6201299 · DOI
  27. [29]Beasley CL Honer WG Bergmann K Falkai P Lutjohann D Bayer TA Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord. (2005) 7: 449– 55. 10.1111/j.1399-5618.2005.00239.x 16176438 · DOI
  28. [30]Olsson AG Angelin B Assmann G Binder CJ Björkhem I Cedazo-Minguez A. Can LDL cholesterol be too low? Possible risks of extremely low levels. J. Intern. Med. (2017) 281: 534– 53. 10.1111/joim.12614 28295777 · DOI
  29. [31]Lyketsos CG Baker L Warren A Steele C Brandt J Steinberg M Depression, delusions, and hallucinations in Alzheimer's disease: no relationship to apolipoprotein E genotype. J. Neuropsychiatr. Clin. Neurosci. (1997) 9: 64– 7. 10.1176/jnp.9.1.64 9017530 · DOI
  30. [33]Jofre-Monseny L Minihane AM Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol. Nutr. Food Res. (2008) 52: 131– 45. 10.1002/mnfr.200700322 18203129 · DOI

Cited by

Sorted by citations

Authors
Li, W., Ban, C., Yue, L., Sun, L., Li, X., & Xiao, S.
Affiliations
  • Shanghai Jiao Tong University (CN)
  • Jiading District Central Hospital (CN)
Corresponding author
  • Sun, Lin
  • Li, Xia
  • Xiao, Shifu
ORCID
Venue
Frontiers in Endocrinology
Publisher
Frontiers Media SA
Published
2020-10-15
Volume
11
Pages
642-642
ISSN
1664-2392 (ISSN-L)
DOI
10.3389/fendo.2020.00642
PMC
PMC7593819
OpenAlex
W3101174727
Cited by
5
References
3
Citations by year
2023: 2 · 2022: 1 · 2021: 2
FWCI
0.91
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81671402, CRC2017ZD02, 19MC1911100)
  • Shanghai Clinical Research Center (19MC1911100)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Keywords
APOE polymorphism, schizophrenia, depressive symptoms, low-density lipoprotein, serum lipids, blood lipid metabolism, elderly patients, Chinese population, genetic association
MeSH terms
Aged, China, Cross-Sectional Studies, Depression, Female, Genotype, Humans, Lipoproteins, LDL, Male, Middle Aged, Schizophrenia, Schizophrenic Psychology, Polymorphism, Single Nucleotide, Apolipoprotein E3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review